{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:48:59Z","timestamp":1791258539122,"version":"4.1.0"},"reference-count":20,"publisher":"American Association for Cancer Research (AACR)","issue":"15","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Constitutive activation of extracellular signal-regulated kinases (Erk1\/2) is frequently implicated in human cancers. Recently, aberrantly activated Erk was also found in brain lesions associated with tuberous sclerosis (TSC). We reported previously that Erk might contribute to tumorigenesis by phosphorylating TSC2 at specific residues, particularly S664. In our present study, 25 TSC-related cortical tubers or subependymal giant cell astrocytomas, as well as tissue microarrays of six types of human cancers, were analyzed for the expression of phospho-Erk (pErk) 1\/2, S664-phospho-TSC2 (pTSC2), and phospho-S6 (pS6) by immunohistochemistry. We found that Erk-mediated TSC2 phosphorylation occurred at a high incidence and positively correlated with mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) activation in TSC-associated brain lesions as well as in various cancers. Interestingly, in certain types of cancers (e.g., breast carcinoma and colon carcinoma), S664-pTSC2 seemed to be a more sensitive marker than pErk. Furthermore, most of the pTSC2-positive samples (\u223c75%) were positive for pS6, but only 40% to 55% of the pS6-positive tumors exhibited TSC2 phosphorylation. Our results show that S664 TSC2 phosphorylation is a marker for Erk-mediated (as opposed to Akt-mediated) mTOR activation in TSC and human cancer. On the basis of these findings, TSC2 phosphorylation at S664 can be used to identify patients that may benefit from antitumor therapy with MAPK and mTOR inhibitors. Importantly, our results indicate that Erk-mediated phosphorylation and inactivation of TSC2 can be critical in development of hamartomatous lesions in TSC and cancer pathogenesis. [Cancer Res 2007;67(15):7106\u201312]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-4798","type":"journal-article","created":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T18:34:13Z","timestamp":1185993253000},"page":"7106-7112","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Identification of S664 TSC2 Phosphorylation as a Marker for Extracellular Signal-Regulated Kinase\u2013Mediated mTOR Activation in Tuberous Sclerosis and Human Cancer"],"prefix":"10.1158","volume":"67","author":[{"given":"Li","family":"Ma","sequence":"first","affiliation":[{"name":"1Cancer Biology and Genetics Program and"},{"name":"2Department of Pathology, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center;"},{"name":"3Graduate Program in Physiology, Biophysics and Systems Biology, Weill Graduate School of Medical Sciences, Cornell University, New York, New York; and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Teruya-Feldstein","sequence":"additional","affiliation":[{"name":"2Department of Pathology, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Bonner","sequence":"additional","affiliation":[{"name":"2Department of Pathology, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Bernardi","sequence":"additional","affiliation":[{"name":"1Cancer Biology and Genetics Program and"},{"name":"2Department of Pathology, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Neal","family":"Franz","sequence":"additional","affiliation":[{"name":"4Pediatrics,"},{"name":"5Neurology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Witte","sequence":"additional","affiliation":[{"name":"4Pediatrics,"},{"name":"6Pathology, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cordon-Cardo","sequence":"additional","affiliation":[{"name":"2Department of Pathology, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Pandolfi","sequence":"additional","affiliation":[{"name":"1Cancer Biology and Genetics Program and"},{"name":"2Department of Pathology, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,8,1]]},"reference":[{"key":"2022061623342867100_B1","doi-asserted-by":"crossref","unstructured":"Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res\u20081998; 74: 49\u2013139.","DOI":"10.1016\/S0065-230X(08)60765-4"},{"key":"2022061623342867100_B2","doi-asserted-by":"crossref","unstructured":"Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-\/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene\u20081999; 18: 813\u201322.","DOI":"10.1038\/sj.onc.1202367"},{"key":"2022061623342867100_B3","unstructured":"Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res\u20081995; 55: 4182\u20137."},{"key":"2022061623342867100_B4","unstructured":"Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH, Murphy LC. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res\u20082002; 8: 1747\u201353."},{"key":"2022061623342867100_B5","doi-asserted-by":"crossref","unstructured":"Milde-Langosch K, Bamberger AM, Rieck G, et al. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1\/2) in breast cancer. Br J Cancer\u20082005; 92: 2206\u201315.","DOI":"10.1038\/sj.bjc.6602655"},{"key":"2022061623342867100_B6","doi-asserted-by":"crossref","unstructured":"Givant-Horwitz V, Davidson B, Lazarovici P, et al. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol\u20082003; 91: 160\u201372.","DOI":"10.1016\/S0090-8258(03)00434-7"},{"key":"2022061623342867100_B7","doi-asserted-by":"crossref","unstructured":"Vicent S, Lopez-Picazo JM, Toledo G, et al. ERK1\/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer\u20082004; 90: 1047\u201352.","DOI":"10.1038\/sj.bjc.6601644"},{"key":"2022061623342867100_B8","doi-asserted-by":"crossref","unstructured":"Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med\u20081999; 5: 810\u20136.","DOI":"10.1038\/10533"},{"key":"2022061623342867100_B9","unstructured":"Govindarajan B, Mizesko MC, Miller MS, et al. Tuberous sclerosis-associated neoplasms express activated p42\/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth. Clin Cancer Res\u20082003; 9: 3469\u201375."},{"key":"2022061623342867100_B10","doi-asserted-by":"crossref","unstructured":"Han S, Santos TM, Puga A, et al. Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res\u20082004; 64: 812\u20136.","DOI":"10.1158\/0008-5472.CAN-03-3277"},{"key":"2022061623342867100_B11","doi-asserted-by":"crossref","unstructured":"Niida Y, Stemmer-Rachamimov AO, Logrip M, et al. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet\u20082001; 69: 493\u2013503.","DOI":"10.1086\/321972"},{"key":"2022061623342867100_B12","doi-asserted-by":"crossref","unstructured":"Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell\u20082005; 121: 179\u201393.","DOI":"10.1016\/j.cell.2005.02.031"},{"key":"2022061623342867100_B13","doi-asserted-by":"crossref","unstructured":"Hedvat CV, Hegde A, Chaganti RS, et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol\u20082002; 33: 968\u201374.","DOI":"10.1053\/hupa.2002.127438"},{"key":"2022061623342867100_B14","doi-asserted-by":"crossref","unstructured":"Curatolo P, Verdecchia M, Bombardieri R. Tuberous sclerosis complex: a review of neurological aspects. Eur J Paediatr Neurol\u20082002; 6: 15\u201323.","DOI":"10.1053\/ejpn.2001.0538"},{"key":"2022061623342867100_B15","unstructured":"Gomez MR. Tuberous sclerosis. 2nd ed. New York: Raven Press; 1988."},{"key":"2022061623342867100_B16","unstructured":"Henske EP, Scheithauer BW, Short MP, et al. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet\u20081996; 59: 400\u20136."},{"key":"2022061623342867100_B17","doi-asserted-by":"crossref","unstructured":"Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol\u20082006; 59: 490\u20138.","DOI":"10.1002\/ana.20784"},{"key":"2022061623342867100_B18","doi-asserted-by":"crossref","unstructured":"Thomas GV, Horvath S, Smith BL, et al. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res\u20082004; 10: 8351\u20136.","DOI":"10.1158\/1078-0432.CCR-04-0130"},{"key":"2022061623342867100_B19","doi-asserted-by":"crossref","unstructured":"Horiguchi A, Oya M, Uchida A, Marumo K, Murai M. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J Urol\u20082003; 169: 710\u20133.","DOI":"10.1016\/S0022-5347(05)63998-5"},{"key":"2022061623342867100_B20","doi-asserted-by":"crossref","unstructured":"Roy HK, Olusola BF, Clemens DL, et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis\u20082002; 23: 201\u20135.","DOI":"10.1093\/carcin\/23.1.201"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/15\/7106\/2865193\/7106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/15\/7106\/2865193\/7106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T03:51:54Z","timestamp":1655437914000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/15\/7106\/533377\/Identification-of-S664-TSC2-Phosphorylation-as-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,1]]},"references-count":20,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2007,8,1]]},"published-print":{"date-parts":[[2007,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-4798","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,1]]}}}